[Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003381
German
Original Title: Abirateronacetat (Prostatakarzinom)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a17-64.html
Year Published: 2018
URL for published report: https://www.iqwig.de/download/A17-64_Abirateronacetat_Nutzenbewertung-35a-SGB-V_V1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Prostatic Neoplasms
  • Prostatic Neoplasms, Castration-Resistant
  • Abiraterone Acetate
  • Antineoplastic Agents
  • Androgen Antagonists
Keywords
  • Abiraterone Acetate
  • Prednisone
  • Prednisolone
  • Androgen Deprivation Therapy
  • Prostatic Neoplasms
  • Benefit Assessment
  • NCT01715285
  • NCT00268476
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.